Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could ease painful skin condition hidradenitis suppurativa

NCT ID NCT05620836

Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tested an oral drug called povorcitinib in 619 adults with moderate to severe hidradenitis suppurativa, a chronic skin condition causing painful abscesses. Participants received either the drug or a placebo for 12 weeks, followed by a 42-week extension. The main goal was to see if the drug reduces abscess and inflammatory nodule counts by at least 50% without worsening other symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Povorcitinib (INCB054707), an oral tablet
What this could lead to
If successful, povorcitinib could become a new oral treatment to reduce painful skin abscesses and inflammation in people with hidradenitis suppurativa.
What could go wrong
This is a completed phase 3 trial, but results are not yet published. The drug may not work better than placebo, and side effects are possible. It is not a cure, and ongoing treatment may be needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

619 people

The number who actually took part.

Started

Feb 2023

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and female participants ≥ 18 years of age. * Diagnosis of moderate to severe HS ≥ 3 months prior to Screening visit. * HS lesions present in ≥ 2 distinct anatomic areas, 1 of which must be at least Hurley Stage II or Hurley Stage III, at both the Screening and Baseline visits. * Total abscess and inflammatory nodule (AN) count ≥ 5 at both the Screening and Baseline visits. * History of inadequate response to an appropriate course of at least 1 conventional systemic therapy for HS (or demonstrated intolerance to, or have a contraindication to, a conventional systemic therapy for HS) * Agree to not use certain topical antiseptics on the areas affected by HS lesions during the placebo-controlled period. * Willingness to avoid pregnancy or fathering children. * Other inclusion criteria apply. Exclusion Criteria: * Draining tunnel count of \> 20 at Screening or Baseline visits. * Women who are pregnant (or who are considering pregnancy) or breastfeeding. * Medical history including thrombocytopenia, coagulopathy or platelet dysfunction; venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, stroke, moderate to severe heart failure, cerebrovascular accident, myocardial infarction, or other significant cardiovascular diseases; Q-wave interval abnormalities; disseminated herpes zoster or dermatomal herpes zoster; disseminated herpes simplex; chronic/recurrent infections; malignancies. * Evidence of infection with TB, HBV, HCV or HIV. * History of failure to JAK inhibitor treatment of any inflammatory disease. * Laboratory values outside of the protocol-defined ranges. * Other exclusion criteria apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hidradenitis suppurativa (HS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hidradenitis hidradenitis suppurativa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hidradenitis suppurativa (HS)

Contacts and locations

Locations

  • Investigative Site AU200

    Liverpool, New South Wales, 02170, Australia

  • Investigative Site AU201

    Carlton, Victoria, 03053, Australia

  • Investigative Site AU202

    Benowa, Queensland, 04217, Australia

  • Investigative Site AU203

    Kotara, New South Wales, 02289, Australia

  • Investigative Site AU204

    Melbourne, Victoria, 03002, Australia

  • Investigative Site AU205

    Kogarah, New South Wales, 02217, Australia

  • Investigative Site AU206

    Woolloongabba, Queensland, 04102, Australia

  • Investigative Site AU207

    Woolloongabba, Queensland, 04102, Australia

  • Investigative Site BG200

    Sofia, 01510, Bulgaria

  • Investigative Site BG201

    Stara Zagora, 06000, Bulgaria

  • Investigative Site BG202

    Sofia, 01463, Bulgaria

  • Investigative Site BG203

    Sofia, 01407, Bulgaria

  • Investigative Site BG204

    Sofia, 01606, Bulgaria

  • Investigative Site CA200

    Surrey, British Columbia, V3V 0C6, Canada

  • Investigative Site CA202

    Calgary, Alberta, T3E 0B2, Canada

  • Investigative Site CA203

    St. John's, A1A 4Y3, Canada

  • Investigative Site CA204

    Edmonton, Alberta, T6G 1C3, Canada

  • Investigative Site CA205

    Fredericton, New Brunswick, E3B 1G9, Canada

  • Investigative Site CA206

    Saint-Jérôme, Quebec, J7Z 7E2, Canada

  • Investigative Site CA207

    Mississauga, Ontario, L4W 0C2, Canada

  • Investigative Site CA208

    Richmond Hill, Ontario, L4C 9M7, Canada

  • Investigative Site DE200

    Kiel, 24105, Germany

  • Investigative Site DE201

    Dessau, 06847, Germany

  • Investigative Site DE202

    Berlin, 10117, Germany

  • Investigative Site DE203

    Bochum, 44791, Germany

  • Investigative Site DE204

    Lübeck, 23538, Germany

  • Investigative Site DE205

    Heidelberg, 69120, Germany

  • Investigative Site DE206

    Mainz, 55131, Germany

  • Investigative Site DE207

    Erlangen, 91054, Germany

  • Investigative Site DE208

    Göttingen, 37075, Germany

  • Investigative Site DK200

    Århus N, 08200, Denmark

  • Investigative Site DK201

    Roskilde, 04000, Denmark

  • Investigative Site ES200

    Manises, 46940, Spain

  • Investigative Site ES201

    Madrid, 28007, Spain

  • Investigative Site ES202

    Las Palmas de Gran Canaria, 35019, Spain

  • Investigative Site ES203

    Alicante, 03010, Spain

  • Investigative Site ES204

    Madrid, 28005, Spain

  • Investigative Site ES205

    Madrid, 28040, Spain

  • Investigative Site FR200

    Antony, 92160, France

  • Investigative Site FR201

    Toulon, 83000, France

  • Investigative Site FR202

    Rouen, 76031, France

  • Investigative Site FR203

    Nice, 06200, France

  • Investigative Site FR204

    Lyon, 69003, France

  • Investigative Site FR205

    Dijon, 21000, France

  • Investigative Site FR206

    Reims, 51100, France

  • Investigative Site GB200

    Dudley, DY1 2HQ, United Kingdom

  • Investigative Site GB201

    Leeds, LS1 3EX, United Kingdom

  • Investigative Site GB202

    Birmingham, B15 2GW, United Kingdom

  • Investigative Site GB203

    Salford, M6 8HD, United Kingdom

  • Investigative Site GB204

    London, SE1 7EH, United Kingdom

  • Investigative Site IT200

    Ancona, 60126, Italy

  • Investigative Site IT201

    Rozzano, 20089, Italy

  • Investigative Site IT202

    Milan, 20122, Italy

  • Investigative Site IT203

    Naples, 80131, Italy

  • Investigative Site IT204

    Brescia, 25124, Italy

  • Investigative Site IT205

    Roma, 00168, Italy

  • Investigative Site IT206

    Pisa, 56126, Italy

  • Investigative Site IT207

    Catania, 95123, Italy

  • Investigative Site PL200

    Rzeszów, 35-055, Poland

  • Investigative Site PL201

    Warsaw, 02-507, Poland

  • Investigative Site PL202

    Warsaw, 02-962, Poland

  • Investigative Site PL203

    Lublin, 20573, Poland

  • Investigative Site US200

    Ocala, Florida, 34470, United States

  • Investigative Site US201

    Tampa, Florida, 33613, United States

  • Investigative Site US202

    New York, New York, 10003, United States

  • Investigative Site US203

    Columbus, Ohio, 43210, United States

  • Investigative Site US204

    Miami, Florida, 33125, United States

  • Investigative Site US205

    Chapel Hill, North Carolina, 27516, United States

  • Investigative Site US206

    Indianapolis, Indiana, 46250, United States

  • Investigative Site US207

    Metairie, Louisiana, 70006, United States

  • Investigative Site US208

    Beverly, Massachusetts, 01915, United States

  • Investigative Site US209

    Louisville, Kentucky, 40241, United States

  • Investigative Site US210

    Rochester, New York, 14642, United States

  • Investigative Site US212

    Minneapolis, Minnesota, 55455, United States

  • Investigative Site US213

    Detroit, Michigan, 48084, United States

  • Investigative Site US214

    Arkansas City, Arkansas, 72758, United States

  • Investigative Site US215

    Bexley, Ohio, 43209, United States

  • Investigative Site US217

    Waterford, Michigan, 48328, United States

  • Investigative Site US218

    Bellaire, Texas, 77401, United States

  • Investigative Site US220

    West Dundee, Illinois, 60118, United States

  • Investigative Site US221

    Quincy, Massachusetts, 02169, United States

  • Investigative Site US222

    San Francisco, California, 94118, United States

  • Investigative Site US223

    Los Angeles, California, 90033, United States

  • Investigative Site US224

    Baltimore, Maryland, 21224, United States

  • Investigative Site US225

    Frankfurt am Main, MA, 60590, Germany

  • Investigative Site US226

    San Diego, California, 92103, United States

  • Investigative Site US227

    Margate, Florida, 33063, United States

  • Investigative Site US228

    Brandon, Florida, 33511, United States

  • Investigative Site US229

    New Orleans, Louisiana, 70115, United States

  • Investigative Site US230

    Hightstown, New Jersey, 08520, United States

  • Investigative Site US232

    Murfreesboro, Tennessee, 37130, United States

  • Investigative Site US233

    Washington D.C., District of Columbia, 20060, United States

  • Investigative Site US234

    San Antonio, Texas, 78213, United States

  • Investigative Site US235

    Arlington, Texas, 76011, United States

  • Investigative Site US236

    Miami, Florida, 33173, United States

  • Investigative Site US237

    Scottsdale, Arizona, 85259, United States

  • Investigative Site US238

    Pflugerville, Texas, 78660, United States

  • Investigative Site US239

    Omaha, Nebraska, 68144, United States

  • Investigative Site US240

    Scottsdale, Arizona, 85255, United States

  • Investigative Site US241

    Iowa City, Iowa, 52242, United States

  • Investigative Site US242

    Fayetteville, Arkansas, 72703, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.